Pharmacotherapy of Zollinger–Ellison syndrome

Bibliography

• Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955;142:709-28
   PubMed Web of Science ®Google Scholar
• Roy PK, Venzon DJ, Feigenbaum KM, Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis - a prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore) 2001;80:189-222
   PubMed Web of Science ®Google Scholar
• Roy PK, Venzon DJ, Shojamanesh H, Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine (Baltimore) 2000;79:379-411
   PubMed Web of Science ®Google Scholar
• Osefo N, Ito T, Jensen RT. Gastric acid hypersecretory States: recent insights and advances. Curr Gastroenterol Rep 2009;11:433-41
   Google Scholar
• Jensen RT, Doppman JL, Gardner JD. Gastrinoma. In: Go VLW, Brooks FA, DiMagno EP, editors. The exocrine pancreas: biology, pathobiology and disease. Raven Press; New York: 1986. p. 727-44
   Google Scholar
• Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg 2009;46:13-106
   PubMed Web of Science ®Google Scholar
• Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469-92
   PubMed Web of Science ®Google Scholar
• Jensen RT, Cadiot G, Brandi ML, ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012;95:98-119
   PubMed Web of Science ®Google Scholar
• Riccardi F, Rizzo M, Festino L, Therapy innovation for the treatment of pancreatic neuroendocrine tumors. Expert Opin Ther Targets 2012;16(Suppl 2):S91-102
   Google Scholar
• Gibril F, Jensen RT. Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep 2004;6:454-63
   PubMedGoogle Scholar
• Wilcox CM, Hirschowitz BI. Treatment strategies for Zollinger-Ellison syndrome. Expert Opin Pharmacother 2009;10:1145-57
   PubMed Web of Science ®Google Scholar
• Jensen RT, Niederle B, Mitry E, Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006;84:173-82
   PubMed Web of Science ®Google Scholar
• Gibril F, Jensen RT. Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep 2005;7:114-21
   Google Scholar
• Norton JA, Fang TD, Jensen RT. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Cancer 2006;4:148-53
   PubMedGoogle Scholar
• Norton JA, Alexander HR, Fraker DL, Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001;234:495-506
   PubMed Web of Science ®Google Scholar
• Norton JA, Jensen RT. Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). Surg Oncol 2003;12:145-51
   PubMed Web of Science ®Google Scholar
• MacFarlane MP, Fraker DL, Alexander HR, A prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia-type 1. Surgery 1995;118:973-80
   PubMed Web of Science ®Google Scholar
• Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004;240:757-73
   PubMed Web of Science ®Google Scholar
• Jensen RT, Berna MJ, Bingham MD, Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management and controversies. Cancer 2008;113(7 Suppl):1807-43
   PubMed Web of Science ®Google Scholar
• Gibril F, Chen Y-J, Schrump DS, Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2003;88:1066-81
   PubMed Web of Science ®Google Scholar
• Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998;243:477-88
   PubMed Web of Science ®Google Scholar
• Gibril F, Schumann M, Pace A, Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. A prospective study of 107 cases and comparison with 1009 patients from the literature. Medicine (Baltimore) 2004;83:43-83
   PubMed Web of Science ®Google Scholar
• Berna MJ, Annibale B, Marignani M, A prospective study of gastric carcinoids and enterochromaffin-like cells changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 2008;93:1582-91
   PubMed Web of Science ®Google Scholar
• Asgharian B, Chen YJ, Patronas NJ, Meningiomas may be a component tumor of MEN1. Clin Cancer Res 2004;10:869-80
   Google Scholar
• Bonaccorsi-Riani E, Apestegui C, Jouret-Mourin A, Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review. Transpl Int 2010;23:668-78
   Google Scholar
• Imamura M, Komoto I, Ota S, Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 2011;17:1343-53
   PubMedGoogle Scholar
• Nieto JM, Pisegna JR. The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome. Expert Opin Pharmacother 2006;7:169-75
   PubMed Web of Science ®Google Scholar
• Auernhammer CJ, Goke B. Medical treatment of gastrinomas. Wien Klin Wochenschr 2007;119:609-15
   Google Scholar
• Ito T, Cadiot G, Jensen RT. Diagnosis of Zollinger-Ellison syndrome: increasingly difficult. World J Gastroenterol 2012;18:5495-503
   PubMed Web of Science ®Google Scholar
• Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol 2012;10:199-202
   PubMed Web of Science ®Google Scholar
• Banasch M, Schmitz F. Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors. Wien Klin Wochenschr 2007;119:573-8
   Google Scholar
• Berna MJ, Hoffmann KM, Long SHSerum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006;85:331-64
   PubMed Web of Science ®Google Scholar
• Berna MJ, Hoffmann KM, Serrano J, Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006;85:295-330
   PubMed Web of Science ®Google Scholar
• Metz DC. Diagnosis of the Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol 2012;10:126-30
   Web of Science ®Google Scholar
• Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr Opin Oncol 2012;24:46-55
   PubMed Web of Science ®Google Scholar
• Pavel M, Baudin E, Couvelard A, Enets consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95:157-76
   PubMed Web of Science ®Google Scholar
• Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol 2012;47:941-60
   PubMed Web of Science ®Google Scholar
• Halperin DM, Kulke MH. Management of pancreatic neuroendocrine tumors. Gastroenterol Clin North Am 2012;41:119-31
   Google Scholar
• Kulke MH, Benson AB III, Bergsland E, Neuroendocrine tumors. J Natl Compr Canc Netw 2012;10:724-64
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Majumder S, Gopal S, Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors. Expert Opin Pharmacother 2012;13:461-71
   PubMed Web of Science ®Google Scholar
• Srirajaskanthan R, Toumpanakis C, Meyer T, Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours. Aliment Pharmacol Ther 2009;29:1143-54
   Google Scholar
• Jensen RT, Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 2011;364:564-5
   PubMed Web of Science ®Google Scholar
• Feldmann G, Bisht S, Schutte U, Everolimus for the treatment of pancreatic neuroendocrine tumors. Expert Opin Pharmacother 2012;13(14):2073-84
   PubMed Web of Science ®Google Scholar
• Sideris L, Dube P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist 2012;17:747-55
   PubMed Web of Science ®Google Scholar
• Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010;16:2963-70
   PubMed Web of Science ®Google Scholar
• Gedaly R, Daily MF, Davenport D, Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg 2011;146:953-8
   Google Scholar
• Lee E, Leon Pachter H, Sarpel U. Hepatic arterial embolization for the treatment of metastatic neuroendocrine tumors. Int J Hepatol 2012;2012:471203
   PubMedGoogle Scholar
• van Vliet EI, Teunissen JJ, Kam BL, Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neuroendocrinology 2012; Epub ahead of print
   Google Scholar
• Teunissen JJ, Kwekkeboom DJ, Valkema R, Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer 2011;18(Suppl 1):S27-51
   PubMedGoogle Scholar
• Kwekkeboom DJ, de Herder WW, Kam BL, Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30
   PubMed Web of Science ®Google Scholar
• Corleto VD, Annibale B, Gibril F, Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 2001;15:1555-61
   PubMed Web of Science ®Google Scholar
• Wong H, Yau T, Chan P, PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success. Pathol Oncol Res 2010;16:87-91
   Google Scholar
• Baldwin CM, Keam SJ. Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2009;69:1373-401
   PubMed Web of Science ®Google Scholar
• Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) 2000;40:52-62
   PubMedGoogle Scholar
• Vachhani R, Olds G, Velanovich V. Esomeprazole: a proton pump inhibitor. Expert Rev Gastroenterol Hepatol 2009;3:15-27
   PubMedGoogle Scholar
• Metz DC, Pisegna JR, Fishbeyn VA, Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992;103:1498-508
   PubMed Web of Science ®Google Scholar
• Frucht H, Maton PN, Jensen RT. Use of omeprazole in patients with the Zollinger-Ellison syndrome. Dig Dis Sci 1991;36:394-404
   Google Scholar
• Metz DC, Pisegna JR, Fishbeyn VA, Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 1993;17:468-80
   PubMed Web of Science ®Google Scholar
• Metz DC, Pisegna JR, Ringham GL, Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci 1993;38:245-56
   PubMed Web of Science ®Google Scholar
• Maton PN, Frucht H, Vinayek R, Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study. Gastroenterology 1988;94:294-9
   PubMed Web of Science ®Google Scholar
• Collen MJ, Howard JM, McArthur KE, Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion. Ann Intern Med 1984;100:52-8
   PubMed Web of Science ®Google Scholar
• Jensen RT. Zollinger-Ellison syndrome. In: Doherty GM, Skogseid B, editors. Surgical endocrinology: clinical syndromes. Lippincott Williams & Wilkins; Philadelphia: 2001. p. 291-344
   Google Scholar
• Pisegna JR, Norton JA, Slimak GG, Effects of curative resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992;102:767-78
   PubMed Web of Science ®Google Scholar
• Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008;134:1842-60
   PubMed Web of Science ®Google Scholar
• Howard JM, Chremos AN, Collen MJ, Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology 1985;88:1026-33
   PubMed Web of Science ®Google Scholar
• Metz DC, Strader DB, Orbuch M, Use of omeprazole in Zollinger-Ellison: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993;7:597-610
   PubMed Web of Science ®Google Scholar
• Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol 2005;3:39-48
   PubMed Web of Science ®Google Scholar
• Weber HC, Venzon DJ, Jensen RT, Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori and proton pump inhibitor therapy. Gastroenterology 1997;112:84-91
   PubMed Web of Science ®Google Scholar
• Murugesan SV, Varro A, Pritchard DM. Review article: strategies to determine whether hypergastrinaemia is due to Zollinger Ellison syndrome rather than a more common benign cause. Aliment Pharmacol Ther 2009;29:1055-68
   Google Scholar
• Raines D, Chester M, Diebold AE, A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas 2012;41:508-11
   Web of Science ®Google Scholar
• Ito T, Igarashi H, Jensen RT. Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors? Pancreas 2012;41:505-7
   PubMed Web of Science ®Google Scholar
• Dhillo WS, Jayasena CN, Lewis CJ, Plasma gastrin measurement cannot be used to diagnose a gastrinoma in patients on either proton pump inhibitors or histamine type-2 receptor antagonists. Ann Clin Biochem 2006;43:153-5
   PubMedGoogle Scholar
• Frucht H, Howard JM, Stark HA, Prospective study of the standard meal provocative test in Zollinger-Ellison syndrome. Am J Med 1989;87:528-36
   PubMed Web of Science ®Google Scholar
• Shibata C, Funayama Y, Fukushima K, The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome. J Gastrointest Surg 2008;12:344-9
   Google Scholar
• Fishbeyn VA, Norton JA, Benya RV, Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Intern Med 1993;119:199-206
   PubMed Web of Science ®Google Scholar
• Norton JA, Venzon DJ, Berna MJ, Prospective study of surgery for primary hyperaparathyroidism (HPT) in multiple endocrine neoplasia type 1 (MEN1), and Zollinger-Ellison syndrome (ZES): longterm outcome of a more virulent form of HPT. Ann Surg 2008;247:501-10
   PubMed Web of Science ®Google Scholar
• Goldman JA, Blanton WP, Hay DW, Case report: false-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2009;7:600-2
   Google Scholar
• Kulke MH, Anthony LB, Bushnell DL, NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010;39:735-52
   PubMed Web of Science ®Google Scholar
• Metz DC, Buchanan M, Purich E, A randomized controlled crossover study comparing synthetic porcine and human secretins with biologically derived porcine secretin to diagnose Zollinger-Ellison Syndrome. Aliment Pharmacol Ther 2001;15:669-76
   Google Scholar
• Long SH, Berna MJ, Thill M, Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results. J Clin Endocrinol Metab 2007;92:4394-402
   Google Scholar
• Jensen RT. Use of omeprazole and other proton pump inhibitors in the Zollinger-Ellison syndrome. In: Olbe L, editor. Milestones in drug therapy. Birkhauser Verlag AG Publish. Co; Basel, Switzerland: 1999. p. 205-21
   Google Scholar
• Franz RC, Penzhorn HO. Is total gastrectomy still a viable option in the management of patients with the Zollinger-Ellison syndrome? S Afr J Surg 2007;45:58-60
   Google Scholar
• Jensen RT, Collen MJ, Allende HD, Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med 1983;308:883-7
   PubMed Web of Science ®Google Scholar
• Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD, editors. The pancreas: biology, pathobiology and disease. Raven Press Publishing Co; New York: 1993. p. 931-78
   Google Scholar
• Metz DC, Sostek MB, Ruszniewski P, Effects of esomeprazole on Acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric Acid hypersecretion. Am J Gastroenterol 2007;102:2648-54
   PubMed Web of Science ®Google Scholar
• McKeage K, Blick SK, Croxtall JD, Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2008;68:1571-607
   PubMed Web of Science ®Google Scholar
• Morocutti A, Merrouche M, Bjaaland T, An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Aliment Pharmacol Ther 2006;24:1439-44
   PubMed Web of Science ®Google Scholar
• Metz DC, Forsmark C, Lew EA, Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Am J Gastroenterol 2001;96:3274-80
   PubMed Web of Science ®Google Scholar
• Metz DC, Comer GM, Soffer E, Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther 2006;23:437-44
   PubMed Web of Science ®Google Scholar
• Jensen RT. Consequences of long-term proton pump blockade: highlighting insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006;98:4-19
   PubMed Web of Science ®Google Scholar
• Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin b(12), iron, and magnesium. Curr Gastroenterol Rep 2010;12:448-57
   PubMedGoogle Scholar
• Termanini B, Gibril F, Sutliff VE III, Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998;104:422-30
   PubMed Web of Science ®Google Scholar
• Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008;27:1110-21
   PubMed Web of Science ®Google Scholar
• Stewart CA, Termanini B, Sutliff VE, Assessment of the risk of iron malabsorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998;12:83-98
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53
   PubMed Web of Science ®Google Scholar
• Capurso G, Marignani M, Attilia F, Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospective case-series and systematic review of the literature. Dig Liver Dis 2011;43:380-5
   Google Scholar
• Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs 2012;72:437-45
   PubMed Web of Science ®Google Scholar
• Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 2012;5:337-44
   PubMed Web of Science ®Google Scholar
• Peghini PL, Annibale B, Azzoni C, Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology 2002;123:68-85
   PubMed Web of Science ®Google Scholar
• Maton PN, Lack EE, Collen MJ, The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 1990;99:943-50
   PubMed Web of Science ®Google Scholar
• Orbuch M, Venzon DJ, Lubensky IA, Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1996;41:604-13
   Google Scholar
• Miller LS, Vinayek R, Frucht H, Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 1990;98:341-6
   PubMed Web of Science ®Google Scholar
• Granberg D, Jacobsson H, Oberg K, Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report. Digestion 2008;77:92-5
   PubMedGoogle Scholar
• Raufman JP, Collins SM, Pandol SJ, Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology 1983;84:108-13
   PubMed Web of Science ®Google Scholar
• Filopanti M, Verga U, Ermetici F, MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. Eur J Endocrinol 2012;167:157-64
   PubMed Web of Science ®Google Scholar
• Moyes VJ, Monson JP, Chew SL, Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism. Int J Endocrinol 2010;2010:906163
   PubMed Web of Science ®Google Scholar
• Stewart CA, Termanini B, Sutliff VE, Management of Zollinger-Ellison syndrome in pregnancy. Am J Obstet Gynecol 1997;176:224-33
   PubMed Web of Science ®Google Scholar
• Matok I, Gorodischer R, Koren G, The safety of H(2)-blockers use during pregnancy. J Clin Pharmacol 2010;50:81-7
   PubMed Web of Science ®Google Scholar
• Gill SK, O'Brien L, Koren G. The safety of histamine 2 (H2) blockers in pregnancy: a meta-analysis. Dig Dis Sci 2009;54:1835-8
   PubMed Web of Science ®Google Scholar
• Gill SK, O'Brien L, Einarson TR, The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009;104:1541-5
   PubMedGoogle Scholar
• Matok I, Levy A, Wiznitzer A, The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci 2012;57:699-705
   PubMed Web of Science ®Google Scholar
• Harper MA, McVeigh JE, Thompson W, Successful pregnancy in association with Zollinger-Ellison syndrome. Am J Obstet Gynecol 1995;173:863-4
   Google Scholar
• Mayer A, Sheiner E, Holcberg G. Zollinger Ellison syndrome, treated with lansoprazole, during pregnancy. Arch Gynecol Obstet 2007;276:171-3
   PubMedGoogle Scholar
• Saeed ZA, Norton JA, Frank WO, Parenteral antisecretory drug therapy in patients with Zollinger- Ellison syndrome. Gastroenterology 1989;96:1393-402
   PubMed Web of Science ®Google Scholar
• Fraker DL, Norton JA, Saeed ZA, A prospective study of perioperative and postoperative control of acid hypersecretion in patients with Zollinger-Ellison syndrome. Surgery 1988;104:1054-63
   PubMed Web of Science ®Google Scholar
• Vinayek R, Hahne WF, Euler AR, Parenteral control of gastric hypersecretion in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1993;38:1857-65
   Google Scholar
• Vinayek R, Frucht H, London JF, Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. Gastroenterology 1990;99:10-16
   Google Scholar
• Lew EA, Pisegna JR, Starr JA, Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 2000;118:696-704
   PubMed Web of Science ®Google Scholar
• Pang SH, Graham DY. A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers. Ther Adv Gastroenterol 2010;3:11-22
   Google Scholar
• Chiang HC, O'Dorisio TM, Huang SC, Multiple hormone elevations in patients with Zollinger-Ellison syndrome: prospective study of clinical significance and of the development of a second symptomatic pancreatic endocrine tumor syndrome. Gastroenterology 1990;99:1565-75
   Google Scholar
• Yu F, Venzon DJ, Serrano J, Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol 1999;17:615-30
   PubMed Web of Science ®Google Scholar
• Maton PN, Gardner JD, Jensen RT. Cushing's syndrome in patients with Zollinger-Ellison syndrome. N Engl J Med 1986;315:1-5
   PubMed Web of Science ®Google Scholar
• Sreevathsa MR, Choudhury A. Long-term survival in a patient with carcinoid syndrome receiving treatment for Zollinger-Ellison syndrome. Int Surg 2009;94:20-2
   Google Scholar
• Morita Y, Suzuki S, Sakaguchi T, Pancreatic neuroendocrine cell tumor secreting parathyroid hormone-related protein and gastrin: report of a case. Surg Today 2010;40:1192-6
   Google Scholar
• Doppman JL, Nieman LK, Cutler GB. Jr., et al. Adrenocorticotropic hormone-secreting islet cell tumors: are they always malignant? Radiology 1994;190:59-64
   PubMed Web of Science ®Google Scholar
• Wynick D, Williams SJ, Bloom SR. Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med 1988;319:605-7
   Google Scholar
• Norton JA, Melcher ML, Gibril F, Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgery. Surgery 2004;136:1267-74
   PubMed Web of Science ®Google Scholar
• Benya RV, Metz DC, Venzon DJ, Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1. Am J Med 1994;97:436-44
   PubMed Web of Science ®Google Scholar
• Thakker RV, Newey PJ, Walls GV, Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012;97:2990-3011
   PubMed Web of Science ®Google Scholar
• Tritos NA, Biller BM. Advances in medical therapies for Cushing's syndrome. Discov Med 2012;13:171-9
   PubMed Web of Science ®Google Scholar
• de Herder WW, van Schaik E, Kwekkeboom D, New therapeutic options for metastatic malignant insulinomas. Clin Endocrinol (Oxf) 2011;75:277-84
   Google Scholar
• Gibril F, Jensen RT. Diagnostic uses of radiolabelled somatostatin-receptor analogues in gastroenteropancreatic endocrine tumors. Dig Liver Dis 2004;36:S106-20
   PubMedGoogle Scholar
• Sutliff VE, Doppman JL, Gibril F, Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 1997;15:2420-31
   PubMed Web of Science ®Google Scholar
• Krudy AG, Doppman JL, Jensen RT, Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography and venous sampling. Am J Roentgenol 1984;143:585-9
   PubMed Web of Science ®Google Scholar
• Alexander RA, Jensen RT. Pancreatic endocrine tumors. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Lippincott Williams & Wilkins; Philadelphia: 2001. p. 1788-813
   Google Scholar
• Cherner JA, Doppman JL, Norton JA, Selective venous sampling for gastrin to localize gastrinomas. A prospective study. Ann Intern Med 1986;105:841-7
   PubMed Web of Science ®Google Scholar
• Doppman JL, Miller DL, Chang R, Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology 1990;174:25-9
   PubMed Web of Science ®Google Scholar
• Gibril F, Doppman JL, Chang R, Metastatic gastrinomas: localization with selective arterial injection of secretin. Radiology 1996;198:77-84
   PubMed Web of Science ®Google Scholar
• Thom AK, Norton JA, Axiotis CA, Location, incidence and malignant potential of duodenal gastrinomas. Surgery 1991;110:1086-93
   PubMed Web of Science ®Google Scholar
• Norton JA, Alexander HR, Fraker DL, Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann Surg 2004;239:617-26
   PubMed Web of Science ®Google Scholar
• von Schrenck T, Howard JM, Doppman JL, Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 1988;94:1326-34
   PubMed Web of Science ®Google Scholar
• Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 2007;21:43-68
   PubMed Web of Science ®Google Scholar
• Frucht H, Doppman JL, Norton JA, Gastrinomas: comparison of MR Imaging with CT, angiography and US. Radiology 1989;171:713-17
   PubMed Web of Science ®Google Scholar
• Gibril F, Reynolds JC, Doppman JL, Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med 1996;125:26-34
   PubMed Web of Science ®Google Scholar
• Gibril F, Doppman JL, Reynolds JC, Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management. J Clin Oncol 1998;16:1040-53
   PubMed Web of Science ®Google Scholar
• Jensen RT. Natural history of digestive endocrine tumors. In: Mignon M, Colombel JF, editors. Recent advances in pathophysiology and management of inflammatory bowel diseases and digestive endocrine tumors. John Libbey Eurotext Publishing Co; Paris, France: 1999. p. 192-219
   Google Scholar
• Norton JA, Fraker DL, Alexander HR, Surgery increases survival in patients with gastrinoma. Ann Surg 2006;244:410-19
   PubMed Web of Science ®Google Scholar
• Toumpanakis C, Meyer T, Caplin ME. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:131-44
   Web of Science ®Google Scholar
• Strosberg JR, Fine RL, Choi J, First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-75
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Coppola D, Klimstra DS, The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (High-Grade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010;39:799-800
   PubMed Web of Science ®Google Scholar
• Nilsson O, Van Cutsem E, Delle Fave G, Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 2006;84:212-15
   PubMed Web of Science ®Google Scholar
• Plockinger U, Wiedenmann B. Biotherapy. Best Pract Res Clin Endocrinol Metab 2007;21:145-62
   PubMed Web of Science ®Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63
   PubMed Web of Science ®Google Scholar
• Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 2005;19:675-97
   PubMed Web of Science ®Google Scholar
• Ramage JK, Ahmed A, Ardill J, Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012;61:6-32
   PubMed Web of Science ®Google Scholar
• Vogl TJ, Naguib NN, Zangos S, Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 2009;72:517-28
   PubMed Web of Science ®Google Scholar
• O'Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19:585-94
   PubMedGoogle Scholar
• Nazario J, Gupta S. Transarterial liver-directed therapies of neuroendocrine hepatic metastases. Semin Oncol 2010;37:118-26
   Google Scholar
• Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J 2010;16:163-75
   PubMed Web of Science ®Google Scholar
• Deleporte A, Flamen P, Hendlisz A. State of the art: radiolabeled microspheres treatment for liver malignancies. Expert Opin Pharmacother 2010;11:579-86
   PubMed Web of Science ®Google Scholar
• Vyleta M, Coldwell D. Radioembolization in the treatment of neuroendocrine tumor metastases to the liver. Int J Hepatol 2011;2011:785315
   Google Scholar
• Kwekkeboom DJ, Teunissen JJ, Bakker WH, Radiolabeled somatostatin analog [177Lu-DOTA0, tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-62
   PubMed Web of Science ®Google Scholar
• Grozinsky-Glasberg S, Barak D, Fraenkel M, Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer 2011;117:1377-85
   Google Scholar
• de Wilde RF, Edil BH, Hruban RH, Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol 2012;9:199-208
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23
   PubMed Web of Science ®Google Scholar
• Capurso G, Festa S, Valente R, Molecular pathology and genetics of pancreatic endocrine tumours. J Mol Endocrinol 2012;49:R37-50
   PubMed Web of Science ®Google Scholar
• Raymond E, Hobday T, Castellano D, Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev 2011;30(Suppl 1):19-26
   PubMed Web of Science ®Google Scholar
• Raut CP, Kulke MH. Targeted therapy in advanced well-differentiated neuroendocrine tumors. Oncologist 2011;16:286-95
   Google Scholar
• Raymond E, Dahan L, Raoul JL, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13
   PubMed Web of Science ®Google Scholar